Your fact-checks will appear here
French pharmaceutical company
The 2025–2026 Northern Hemisphere flu vaccines are trivalent and chosen to target one H1N1 A strain, one H3N2 A strain, and one B/Victoria-lineage strain; U.S. regulators (FDA/CDC) recommended these c...
The 2025–2026 Northern Hemisphere (U.S.) influenza vaccine is trivalent: it includes two influenza A subtypes (H1N1 and H3N2) and one influenza B (B/Victoria lineage) strain, with specific candidate v...
Major vaccine-makers show wide variation in margins driven by product mix (high-margin biologics/vaccines vs. pandemic-era COVID shots), inventory charges and one‑off items: Pfizer’s recent adjusted o...
The Advisory Committee on Immunization Practices (ACIP) voted 8–3 to remove the long-standing universal newborn hepatitis B (Hep B) birth‑dose recommendation, shifting to individual/shared decision‑ma...
There is no reporting in the documents provided that says Donald Trump personally invested capital into pharmaceutical companies or pharmaceutical-focused investment funds; the available sources descr...
For the 2025–26 U.S. season, most manufacturers are supplying single‑dose, thimerosal‑free prefilled syringes — specifically GSK’s Fluarix and Flulaval, Seqirus’s Afluria and Fluad, and CSL Seqirus’s ...
The 2025–2026 U.S. influenza season features a clear policy tilt: public-health advisers and CDC/ACIP recommend using single‑dose formulations that are free of thimerosal for children, pregnant people...
Nine major drugmakers — Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech (Roche’s U.S. unit), Gilead Sciences, GSK (including ViiV), Merck, Novartis and Sanofi — agreed to sell selected me...
Yes — nine major pharmaceutical companies publicly agreed to lower the price of some of their medicines in deals announced by the Trump administration on Dec. 19, 2025, committing to “most-favored-nat...
For the 2025–26 northern hemisphere influenza season, health authorities recommended trivalent vaccines containing an A(H1N1) pdm09–like virus, an A(H3N2)–like virus, and a B/Victoria–lineage virus. U...
Pfizer has publicly released detailed phase 3 results and “full data” from its mRNA influenza vaccine trial showing a 34.5% higher efficacy versus a standard egg‑based comparator in a study of >18,000...
Available reporting in the provided sources does not list a single, clear range of profit margins for vaccine producers; instead, market reports focus on revenues, market size and growth projections (...
Prescription erectile dysfunction (ED) drugs are with known dosing, interactions, and efficacy, while most over-the-counter (OTC) ED products are with uncertain benefit and different safety profiles ....